Fig. 5
From: RRP9 promotes gemcitabine resistance in pancreatic cancer via activating AKT signaling pathway
RRP9 overexpression activates the AKT signaling pathway in PC cells. A AKT activity was measured in RRP9-overexpressing or RRP9-silenced cells with a luciferase reporter assay. Data are expressed as mean ± SD, n = 3. B Western blot analysis of AKT and apoptotic markers, BAD and caspase-9, protein expression in RRP9-overexpressing or RRP9-silenced cells. GAPDH acted as the loading control. C Colony formation was measured in control and RRP9-overexpressing cells treated with gemcitabine or gemcitabine plus AKT inhibitor (MK-2206). Representative colony formation images (left) and quantification (right) are shown. Data are presented as mean ± SD, n = 3. D FACS analysis (upper panel) and quantification (lower panel) of control and RRP9-overexpressing cells treated with gemcitabine or gemcitabine plus AKT inhibitor. Data are expressed as mean ± SD, n = 3. Note: *p < 0.05, **p < 0.01